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Summary 
CD40-CD40 ligand (CD40L) interaction is required for the generation of antibody responses 
to  T-dependent antigens as well as for the development of germinal centers and memory B 
cells.  The role of the CD40-CD40L interaction in the induction  of antigen-specific Th cells 
and in mediating Th cell effector functions other than cognate help for B  cells is less well un- 
derstood. Using CD40- and CD40L-deficient mice together with lymphocytic choriomenin- 
gitis virus and vesicular stomatitis virus as viral model antigens, this study corroborates earlier 
findings that no Ig isotype switching of virus-specific antibodies was measurable upon infection 
of CD40- or CD40L-deficient mice. In contrast, in vivo induction of virus-specific CD4 + T 
cells measured by proliferation and cytokine secretion of primed virus-specific Th cells in vitro 
was not crucially dependent  on the CD40-CD40L interaction.  In addition,  virus-specific Th 
cells primed in a CD40-deficient environment,  adoptively transferred into  CD40-competent 
recipients, were able to mediate Ig isotype switch. Th-mediated effector functions distinct from 
and in addition to T-B collaboration were analyzed in CD40- and CD40L-deficient and nor- 
mal mice: (a) local inflammatory reactions upon LCMV infection mediated by LCMV-specific 
Th cells were not dependent on a functional CD40-CD40L interaction, (b) cytokine-mediated 
protection by CD4 + T  cells primed by vesicular stomatitis virus against a chal/enge infection 
with recombinant vaccinia virus expressing the glycoprotein of vesicular stomatitis virus was 
found to be equivalent in CD40L-deficient and normal mice. 
Thus,  CD40-CD40L interaction plays a crucial role in T-B interactions for Th-dependent 
activation orb cells but not, or to a much lesser extent, in T cell activation, antigen-specific Th 
cell responses in vitro, and for interleukin-mediated Th cell effector functions in vivo. 
I 
t has been established both in vitro and in vivo that the 
interaction  between  CD40  on  B  cells  and  its  ligand 
CD40L,  which  is  expressed  on  activated  Th  cells,  is  re- 
quired for Ig isotype switching, Ig-production and the for- 
marion of germinal centers (1-8). In vivo, administration of 
anti-CD40L antibody or soluble CD40L (9,  10) or CD40- 
Ig  fusion  protein  (1)  as  well  as  studies  in  CD40-  or 
CD40L-deficient mice (11-13) have shown that the gener- 
ation of primary and secondary humoral immune responses 
and the formation of germinal centers to a variety of thy- 
mus-dependent antigens were abrogated. Furthermore, pa- 
tients with hyper-IgM (HIGM) 1 syndrome, a genetic disor- 
der  due  to  mutations  in  the  CD40L  gene,  exhibit  an 
inability  to  respond  to  thymus-dependent  antigens  and 
have secondary lymphoid organs which are devoid of ger- 
minal centers. Nevertheless, patients suffering from HIGM 
1Abbreviations used in  this paper: DNP,  dinitrophenol; HEL, hen  egg 
lysozyme;  HIGM, hyper-IgM  syndrome; KLH, keyhole  limpet hemocya- 
nine; LCMV, lymphocytic  choriomeningitis virus; LCMV-DNP, DNP 
covalently coupled to LCMV; OVA, ovalburnin; VacCGIND,  recombinant 
vaccinia virus expressing  VSV glycoprotein;  VSV, vesicular  stomatitis  virus. 
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susceptible to  viral infections  than  healthy individuals  (6, 
14-18). This may be due to the presence oflgM antibodies 
and/or CD40L-independent T  cell functions. 
Since CD40 is not expressed solely on B  cells but also on 
dendritic  cells,  follicular  dendritic  cells,  monocytes,  he- 
matopoietic  progenitor  cells,  and  epithelial  cells  (19-23) 
CD40-CD40L  interaction might be important for the in- 
duction and/or effector phase  of Th  cells in general. This 
question was adressed in this study. We confirmed here in 
two infectious virus disease models that a functional CD40- 
CD40L interaction is not required for T  help-independent 
anti-viral IgM responses but is strictly required for T-depen- 
dent Ig class switching of virus-specific B  cells. This study 
additionally  investigated  the  importance  of  the  CD40- 
CD40L  interaction for the induction of Th  cell responses 
and  for  Th  cell  effector  functions  other  than  cognate  T 
help for B  cells. 
Using either CD40-  or CD40L-deficient mice, Th cell- 
mediated antiviral immune  responses upon  infection with 
lymphocytic  choriomeningitis virus  (LCMV)  or  vesicular 
stomatitis virus (VSV) were investigated. We found that ac- 
tivation and proliferation of virus-specific Th cells did not 
require  a  functional  CD40-CD40L  interaction.  Effector 
functions of Th cells were characterized by (a) the analysis 
of antiviral humoral immune  responses,  (b)  Th  cell-medi- 
ated inflammatory reaction upon LCMV infection, and (c) 
Th cell-mediated antiviral protection against vaccinia virus. 
Whereas  IgM to  IgG switch was  completely abrogated in 
both CD40- and CD40L-deficient mice, the two latter ef- 
fector  functions  were  comparable  in  CD40-deficient, 
CD40L-deficient,  and  normal  mice,  demonstrating  a  di- 
chotomy  in  the  role  of CD40-CD40L  interaction  in  Th 
cell effector functions. 
Materials  and Methods 
Mice.  Inbred C57BL/6  (H-2  b) mice were obtained from the 
breeding  colony  of the  Institut  ftir  Zuchthygiene  (Tierspital 
Ziirich,  Switzerland).  The  generation  of  mice  deficient  for 
CD40, CD40L, or IgM expression has been described previously 
(11,  12, 24).  Mice were bred in a conventional mouse house fa- 
cility. 
Viruses.  The  LCMV isolate WE was originally provided by 
Dr. F. Lehmann-Grube, Hamburg, Germany and grown on L929 
cells  (ATCC  CR.L  1;  American  Type  Culture  Collection 
[ATCC], Rockville, MD) with a low multiplicity of infection. 
VSV  Indiana  (Mud&Summers  isolate)  seeds,  originally ob- 
tained from D. Kolakofsky (University of Geneva), were grown 
on BHK-21  (CRL 8544; ATCC) cells infected at low multiplic- 
ity and plaqued on Vero cells. 
Vaccinia virus expressing the glycoprotein of VSV was a gen- 
erous gift of Dr. B. Moss (Laboratory of Viral Diseases,  National 
Institutes of Health, Bethesda, MD)  (25).  Recombinant viruses 
were  grown  at low multiplicity of infection on BSC  cells and 
plaqued on BSC cells. 
The  recombinant baculovirus expressing the LCMV  nucleo- 
protein  has  been  previously described  (26).  The  recombinant 
baculovirus was derived from nuclear polyhedrosis virus and was 
grown at 28~  in Spodopterafrugiperda cells in spinner cultures in 
TC-100 medium. Recombinant proteins were produced as pre- 
viously described (27). 
T Cell Proliferation.  Mice were immunized intravenously with 
200  PFU LCMV-WE.  14  d  later, CD4 + T  cells were purified 
from spleen cell suspensions by MACS-sorting according to the 
protocol of the  supplier  (Miltenyi Biotec,  Bergisch  Gladbach, 
Germany).  1  X  10  s  CD4*  T  cells were  incubated in 96-wells 
with threefold serial dilutions of either purified, UV-inactivated 
LCMV  (concentrations  shown  for  CD40L-/-,  CD40-/-, 
IgM-/-  and C57BL/6  ranged between 0.1  p,g/ml and  1 Ixg/ 
ml),  P13  (concentrations shown  for  CD40L-/-,  CD40-/-, 
IgM-/-,  and C57BL/6  ranged between 0.1  p~g/ml and 1 b~g/ 
ml)  or  medium  only  in  the  presence  of 7  ￿  10  s  irradiated 
(2000cGy)  C57BL/6  spleen cells for 3  d.  Proliferation was  as- 
sessed  by  incorporation  of [3H]thymidine  (25  ~Ci/well).  P13 
represents an I-Ab-restricted  T  cell epitope of the glycoprotein of 
LCMV which has been described elsewhere (28). We have previ- 
ously shown that P13 is presented in vivo during a primary im- 
mune  response  against LCMV  and  that  P13-specific  CD4 §  T 
cells are induced in vivo (28). 
Cytokine Analysis.  Supematants of proliferation assays as de- 
scribed above were analyzed for IL-2 content (24 h after restimu- 
lation), IFN~/content (60 h after restimulation), and IL-4 content 
(60  h  after restimulation). IL-2 was determined using the IL-2- 
dependent  cell line CTLL-2.  Quantification of viable cells was 
performed by AlamarBlue  TM  color reaction (Biosource, Interna- 
tional, Camarillo, CA) and measured by fluorescence emission at 
590 nm using the CytoFluor  TM  2350  (Millipore Corp., Bedford, 
MA) fluorimeter. IFN~/and IL-4 were assessed by ELISA as de- 
scribed (29, 30). 
Adoptive Transfer of Primed Th Cells Followed by Challenge with 
DNP-modifiedLCMV.  CD40-deficient  and  CD40-competent 
mice as well as IgM-deficient mice were immunized with 200 
PFU of LCMV-WE into both hind foot pads.  18 d later, single 
cell suspensions  were  prepared from  spleens.  6  ￿  107  primed 
spleen cells  or an equivalent number  of naive cells were trans- 
ferred intravenously into naive, sex-matched C57BL/6 recipients. 
Donor cells were pooled from two  to three individuals. A  few 
hours  later mice were challenged intravenously with 0.4  Ixg of 
purified  LCMV  to  which  DNP  has  been  covalently coupled 
(LCMV-DNP)  (31). Mice were bled 9 d later and DNP-specific 
IgG titers were determined by ELISA. The optimal dose for the 
challenge immunization with LCMV-DNP was determined by in 
vivo titration of the LCMV-DNP stock in naive versus LCMV- 
primed mice. The optimal dose was chosen such that only LCMV- 
primed mice but not naive mice gave rise to a DNP-specific IgG 
titer. 
In addition, the  same adoptive transfer experiment was  per- 
formed using purified, LCMV-primed CD4 + T  cells for transfer. 
CD40-deficient  and  heterozygous littermates were  immunized 
with 200 PFU LCMV i.v. 14 d later, CD4 + T cells were purified 
from spleen cell suspensions by MACS-sorting according to the 
protocol of the supplier (Miltenyi Biotec) and were used at a pu- 
rity of at least 95% as checked by FACS analysis. 6 ￿  106 purified 
T cells were adoptively transferred into naive C57BL/6 recipients 
and  challenged with  0.4  btg  LCMV-DNP.  Whole  spleen  cell 
transfer from LCMV-primed CD40-deficient mice served as pos- 
itive control. Mice were bled 10 d later and DNP-specific IgG ti- 
ters were determined by ELISA. 
ELISA.  The LCMV nucleoprotein-specific ELISA has been 
described previously  (26).  96-well  plates  (Petra  Plastik,  Chur, 
Switzerland)  were  incubated  with  LCMV  nucleoprotein  (0.01 
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preincubated with 2% bovine serum albumin in phosphate-buff- 
ered saline for 2 h and washed, and serial dilutions of serum sam- 
ples (30-fold prediluted) were added to the wells and incubated 
for 90 rain. Plates were washed and incubated with horseradish 
peroxidase-labeled goat anti-mouse IgG (Sigma Chem.  Co., St. 
Louis, MO).  After 90  rain, plates were  washed and developed 
with  ABTS  (5  mg  of  2,2'-azino-di-3-ethyl-benzthiazolinsul- 
fonate and 20 I.L1 ofH20 2 in 50 ml ofNaHCO 3 [pH 4]). Optical 
densities were determined at 405 nm. 
ELISA-measurement  of  DNP-specific  IgG  titers  was  per- 
formed similarly. ELISA plates were coated with 0.25 Ixg/well of 
Ovalbumin covalently coupled to DNP (31, 32). 
VSV-specific Serum Neutralization Test.  Neutralizing  titers  of 
sera were determined as described (33).  Sera were prediluted 40- 
fold in supplemented MEM  and heat-inactivated for 30 rain at 
56~  Serial twofold dilutions were mixed with equal volumes of 
virus diluted to contain 500 PFU/ml. The mixture was incubated 
for 90 rain at 37~  in an atmosphere containing 5% CO2.  100 ~1 
of  the  serum-virus  mixture  were  transferred  onto  Vero  cell 
monolayers in 96-well plates and incubated for 1 h at 37~  The 
monolayers were then overlaid with  100  Ixl DMEM containing 
1% methyl cellulose. After incubation for 24 h at 37~  the over- 
lay was removed and the monolayer was fixed and stained with 
0.5%  crystal violet. The  highest dilution of the  serum that  re- 
duced the number of plaques by 50% was taken as the neutraliz- 
ing titer. To determine IgG titers, undiluted serum was first pre- 
treated with an equal volume of 0.1 M 2-ME in saline (34). 
Assessment of Foot Pad Swelling.  Mice  were  inoculated  with 
30 PFU of LCMV-WE into both hind foot pads and foot pad 
swelling was assessed daily with a spring-loaded caliper (35).  In 
vivo anti-CD4 treatment was performed at day 6 and 8 after in- 
oculation using the monoclonal antibody YTS 191.1  (36). 
Protection of Mice from  Replication of Recombinant  Vaccinia Vi- 
rus.  Mice were immunized with 2  ￿  106 PFU VSV and chal- 
lenged i.p. 8 d later with 5 ￿  106 PFU recombinant vaccinia virus 
expressing VSV-glycoprotein (VaccGlrqD). Vaccinia titers in ova- 
ries were determined 5 d later as described previously (37). Titers 
are shown as log10 PFU per animal. 
Results 
Induction  of Virus-specific Th Cells.  In  some  experimen- 
tal systems B  cells have been shown  to be crucial for effi- 
cient T  helper cell induction (38-44).  In addition, CD40 is 
not  solely expressed on B  cells but  also  on  dendritic cells 
and follicular dendritic cells (6). We addressed therefore the 
question  whether  CD40-CD40L  interaction  or  the  pres- 
ence of B  cells serving as antigen presenting cells is required 
for  the  induction  of virus-specific Th  cells  in  vivo.  We 
compared the induction ofLCMV-specific Th cells in vivo 
in  CD40-deficient,  CD40L-deficient,  normal  C57BL/6, 
and  IgM-deficient mice.  Since it can  be  expected  that B 
cells  do  not  serve  efficiently as  APCs  in  the  absence  of 
proper activation and proliferation induced by the CD40- 
CD40L  interaction,  IgM-deficient mice  that  do  not  have 
peripheral B  cells  (24)  were  included in  this  comparison. 
This made possible the distinction between Th cell induc- 
tion without the CD40-CD40L interaction and Th cell in- 
duction without B  cells serving as antigen-presenting cells. 
Induction of LCMV- or peptide P13-specific Th cells in 
vivo was comparable in CD40L-,  CD40,- and B  cell-defi- 
cient mice and in normal C57BL/6 mice as defined by spe- 
cific  proliferation  in  response  to  both  antigens  (Fig.  1). 
These  results demonstrate that LCMV-specific Th  cells are 
induced in vivo independent of a functional CD40-CD40L 
interaction. Since induction of LCMV-specific Th  cells in 
CD40-deficient as well as in CD40L-deficient mice and B 
cell-deficient mice  was  similar,  Th  cells can  apparently be 
stimulated in vivo without crucial involvement of B  cells or 
of a  functional CD40-CD40L-interaction  after LCMV  in- 
fection. 
In addition, cytokine secretion patterns were analyzed in 
the  supernatants  recovered  from  the  proliferation  assays 
performed with LCMV-primed CD4 + T  cells from CD40- 
deficient,  CD40L-deficient,  or  control  C57BL/6  mice 
(Fig.  2).  IL-2  and  IFN~/  were  secreted  in  comparable 
amounts  by  CD4 +  T  cells  originating  from  CD40-defi- 
cient,  CD40L-deficient,  or control mice whereas no  IL-4 
could be detected in the same supernatants  (Fig. 2).  Thus, 
the Thl  cytokine secretion pattern which is normally ob- 
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Figure  1.  LCMV-specific proliferation of purified Th cells. CD40L- 
deficient, CD40-deficient, IgM-deficient, and C57BL/6 mice were im- 
munized with LCMV and 14 d later LCMV-specific proliferation of  puri- 
fied CD4 + T cells was determined using either UV-inactivated LCMV 
(WE) or peptide 13 (P13) as LCMV-specific antigens (concentrations of 
stimulating antigens are described in Materials and Methods). P13 is a 
LCMV-GP-derived peptide recognized by CD4 § T cells. Stimulation in- 
dices were  calculated in  relation to  proliferation in  medium  control. 
Background cpm counts in medium control were always ~2,000 cpm. 
Two of four equivalent experiments are shown. 
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Figure  2.  LCMV-specific cytokine secretion. In vivo LCMV-primed 
CD40-,  CD40L-deficient or control CD4 + T cells were restimulated in 
vitro with the  LCMV-glycoprotein-derived  I-Ab-binding peptide  P13 
(circles) or without antigen (medium control (squares). IL-2 content in the 
supernatants (5,000 EM U  correspond to 30 U  IL-2/ml)  was analyzed 
24 h after restimulation (top) whereas IFN3' (OD  =  0.5 corresponds to 
500 U IFN"//ml) and IL-4 levels (OD =  0.5 corresponds to 25 U IL-4/ 
rot) were assessed 60 h after restimulation (middle and bottom).  Recombi- 
nant IL-4 (open circles) served as positive control in the IL-4 ELISA. Each 
line represents a separate prohferation assay from an individual mouse. 
One of  three equivalent experiments is shown. 
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Figure  3.  Cognate  help  to  CD40-expressing B  cells after adoptive 
transfer of LCMV-primed Th cells. CD40-deficient mice (triangles) and 
heterozygous littermates (circles) as well as IgM-deficient mice (diamonds) 
and control mice (circles) were Lmmunized with LCMV. 20 d after infec- 
tion spleen cells were adoptively transferred into CD40 competent naive 
recipients and the recipients as well as naive CD40 competent control an- 
imals (squares) were challenged with LCMV-DNP.  After 9 d, DNP-spe- 
cific IgG titers were determined by ELISA  from 30-fold prediluted sera. 
Each line represents one individual mouse. One of three similar experi- 
ments is shown. Transfer of naive CD4 + cells from CD40 -/- donors did 
not result in the generation of significant DNP-specific [gG antibodies 
(data not shown). 
served for LCMV-specific Th cells is not influenced by the 
absence of functional CD40-CD40L interactions. 
In a second experimental approach, induction of LCMV- 
specific Th  cells was  assessed in CD40-deficient mice and 
in  heterozygous  littermates  (both  being  competent  for 
CD40L  on Th  cells) by measuring T  helper cell function 
upon transfer of primed Th cells into CD40-competent na- 
ive recipients. Thus,  CD40L  competent cells were primed 
in  a  CD40-deficient  environment.  Adoptive  transfer  of 
CD40L-positive, LCMV-primed Th cells into naive recip- 
ients with  normal CD40 +  B  cells restores functional T-B 
cooperation.  The  conditions for challenging the  recipient 
mice were chosen such that only Th cells already primed in 
the  CD40-deficient donors were  able to  induce  a  signifi- 
cant isotype switch in the  recipient. To  assess  the impor- 
tance of B  cells for the induction of Th cells, B  cell-deficient 
mice were included in the experiment. CD40-deficient, B 
cell-deficient and control mice were infected with LCMV 
and  18  d  after infection spleen cells were  transferred into 
naive recipients. This was followed by a challenge immuni- 
zation  with  LCMV-DNP.  DNP-specific  IgG  antibodies 
were  only significantly induced after challenge if LCMV- 
specific Th cells had been induced in the donor animals be- 
fore transfer (Fig. 3). Since B  cells in the recipients express 
CD40,  equivalent  DNP-specific  IgG  titers  in  recipients 
that received primed Th cells from immunized CD40-defi- 
cient mice  or from  heterozygous littermates revealed that 
induction  of LCMV-specific  Th  cells was  not  dependent 
on a  functional  CD40-CD40L  interaction  in vivo (Fig.  3, 
A  and B).  Similarly, equivalent  IgG titers in recipients that 
received Th cells from LCMV-immunized  B  cell-deficient 
mice or B  cell-competent C57BL/6 mice indicated that in- 
duction  of LCMV-specific Th  cells was not dependent on 
the  presence  of B  cells serving as  antigen presenting cells 
(Fig. 3,  C  and D). 
To confirm that the transferred CD4  + T  cells were alone 
responsible for the enhanced DNP-specific IgG titers, puri- 
fied  CD4 +  T  cells  from  LCMV-primed  CD40-deficient 
mice or heterozygous httermates were transferred into na- 
ive C57BL/6  recipients which  were  challenged by injec- 
tion of LCMV-DNP.  DNP-specific IgG titers were deter- 
mined 10 d  later (Fig. 4, A  and B).  In addition, transfer of 
unseparated spleen cells from  LCMV-primed  CD40-defi- 
cient donors into naive C57BL/6  recipients served as posi- 
tive control (Fig. 4  C), whereas unmanipulated, unprimed 
C57BL/6  mice served as negative control. Both  CD4 +  T 
cells  originating  from  either  LCMV-primed  CD40-defi- 
cient mice or heterozygous littermates were able to compa- 
rably provide help for CD40-competent B  cells (Fig. 4, A 
and B), albeit whole spleen cell transfers resulted in a more 
pronounced  enhancement  of DNP-specific  IgG  titers  as 
compared to purified CD4 + T  cells. 
Thus,  three  independent  assays showed that  the induc- 
tion of LCMV-specific Th  cell responses was  not  limited 
by CD40-CD40L  interactions and  was  independent  of B 
cells acting as critical APCs. 
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Figure  4.  Cognate help to  CD40-expressing B  cells after adoptive 
transfer of purified, LCMV-primed CD4  + T cells. CD40-deficient mice 
(triangles) and heterozygous littermates (circles) were immunized with 200 
PFU LCMV i.v. 14 d later CD4  + T cells were purified and adoptively 
transferred into CD40-competent, naive recipients (A and B). In addi- 
tion, spleen cells from LCMV-primed CD40-deficient donors (diamonds) 
were transferred into CD40-competent naive recipients (C). All recipi- 
ents as  well as  naive control animals (squares) were challenged with 
LCMV-DNP and 10 d later DNP-specific ]gG titers were determined in 
90-fold prediluted sera. Each line represents an individual  recipient. One 
of two similar  experiments  is shown. 
Th Cell Effector Function:  Cognate Help to B  Cells.  It  has 
already been demonstrared in detail that T-dependent IgG 
humoral  immune  responses  are  strictly  dependent  on  a 
functional CD40-CD40L  interaction and  that  a  missing 
ligand in  this  complex  totally  abrogates  germinal center 
formation as  well  as  immunoglobulin isotype  switch  and 
generation of memory B cells (1-10). To ensure that Ig re- 
sponses to LCMV as a model viral antigen require CD40- 
CD40L engagement, we infected CD40-, CD40L-deficient, 
or C57BL/6 mice with LCMV and then measured antiviral 
primary antibody responses. VSV was used as a second viral 
model antigen. 
Infection of normal mice with  LCMV  leads  to  a  pro- 
nounced IgG  response  specific  for  the  nucleoprotein of 
LCMV (LCMV-NP) (Fig. 5). In contrast, no LCMV-NP- 
specific IgG titers were obtained using CD40L- or CD40- 
deficient mice (Fig. 5). Thus, CD40-CD40L interaction is 
crucial for isotype class  switching in response to  LCMV- 
infection. 
In addition, we analyzed virus neutralizing antibody re- 
sponses in CD40L-deficient and normal mice after infec- 
tion with VSV. VSV infection of mice normally induces a 
type I  T-independent neutralizing IgM-response followed 
by a  T-dependent neutralizing IgG response  (45-47).  As 
expected control C57BL/6 mice mounted high neutraliz- 
ing IgM and IgG responses  (Fig. 6).  In contrast, CD40L- 
deficient mice mounted a neutralizing T-independent IgM 
response but no VSV-specific IgG was detected upon VSV 
infection (Fig.  6).  The  same  results  were  obtained using 
CD40-deficient mice (data not shown). These data corrob- 
orate previous findings in nonviral systems, demonstrating 
that cognate T-B cooperation leading to Ig class switching 
is  critically dependent on functional CD40-CD40L inter- 
actions. 
Th  Cell Effector Function:  Inflammatory  Reaction.  Infec- 
tion of normal mice with LCMV in the hind footpads in- 
duces  a  local inflammatory reaction consisting of two  se- 
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Figure  5.  LCMV-NP specific IgG antibody response. CD40L-defi- 
cient (circles),  'CD40-deficient (triangles) and normal C56BL/6 (squares) 
mice were immunized with LCMV. LCMV-NP-specific  IgG titers were 
determined 7, 10, and 21 d after infection for CD40L-deficient  and nor- 
mal C56BL/6 mice. LCMV-NP specific IgG titers in CD40-deficient 
and normal C57BL/6 mice were assessed 20 d after LCMV infection in 
30-fold prediluted sera. Each line represents one individual  mouse. Varia- 
tions were smaller  than two dilution steps. One of three comparable ex- 
periments is shown. 
quential swelling phases.  A  pronounced swelling reaction 
mediated by CD8 + T  cells is observed 7-10 d  after infec- 
tion; this is followed by a CD4  §  T  ceU-mediated swelling 
phase declining around day 14-16 after infection (46, 48). 
The second phase of the swelling reaction exhibits no sharp 
peak but has the shape of a shoulder. We analyzed whether 
or not the second swelling phase mediated by LCMV-spe- 
cific CD4 § T  cells was dependent on CD40-CD40L inter- 
actions. CD40-deficient mice as well as heterozygous litter- 
mates were infected with LCMV in both hind footpads and 
the subsequent swelling reaction was monitored daily (Fig. 
7 A). In fact, there was a tendency noted that CD40-defi- 
_o,  CD40L+/+ 
~  8 
~  O~  ,  , 
z  0  5  10  15  20 
CD40L-/- 
0  5  10  15  20 
IgM 
IgG 
Days after immunization 
Figure 6.  VSV neutralizing antibody response. CD40L-deficient and 
C57BL/6 mice were immunized with VSV. VSV-neutralizing  IgM titers 
(squares) and VSV-neutralizing  IgG tilters (triangles) were determined from 
40-fold prediluted sera 4, 6, 8, 12, and 20 d after infection.  Each line rep- 
resents one individual mouse. One of three comparable experiments is 
shown. 
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Figure 7.  LCMV-specific foot pad swelling reaction. In A CD40-defi- 
cient mice (triangles)  and heterozygous  litterrnates  (squares) were immunized 
into the footpads with 200 PFU of LCMV and the local LCMV-specific 
foot pad swelling reaction was daily monitored. In B LCMV-specific foot 
pad swelling reaction was similarly analyzed in CD40L-deficient (circles) 
and normal C57BL/6 mice (squares) as well as in anti-CD4 treated C57BL/6 
mice (diamonds). Each line represents one individual mouse. 
cient mice exhibited a slightly increased maximal early CD8- 
dependent peak response and that subsequently the CD4- 
dependent  shoulder  tended  to  be  slightly  higher.  Thus, 
neither the  CD8 +  T  cell-mediated swelling phase  nor in 
the  CD4 +  T  cell-mediated swelling phase was  dependent 
upon  a  functional  CD40  molecule.  Compatible  results 
were obtained with CD40L-deficient mice (Fig. 7  B). This 
indicates comparable abilities to mount LCMV-specific in- 
flammatory reactions in the presence or absence of CD40- 
CD40L  interaction.  To  confirm  that  the second phase of 
the swelling reaction was  actually CD4 +  T  cell mediated, 
C57BL/6  mice were treated with a CD4 + T  cell-depleting 
v 
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8 
O 
>, 
_a  ~,  ua 
o  o  z 
monoclonal antibody at day 6  and 8  after inoculation with 
LCMV.  Foot pad swelling was less marked and the subse- 
quent decline was much more rapid compared to untreated 
controls (Fig. 7  B). 
Th Cell Erector Function: AntiviraI Protection.  A  third  Th 
cell erector function was analyzed in CD40L-deficient and 
normal mice. VSV primed C57BL/6 mice have been shown 
to rapidly control replication of a recombinant vaccinia vi- 
rus  expressing the  glycoprotein of VSV  (VaccGN)).  This 
antiviral protective mechanism is virtually exclusively me- 
diated by IFNy and TNF~ which are secreted by VSV gly- 
coprotein-specific CD4 + T  cells (37, 49). Neither CD8 + T 
cells nor VSV-neutratizing antibodies have been shown to 
be  protective  in  this  infection.  Because  GIN  D  is  not  ex- 
pressed in the VaccGIND envelope, VSV-specific antibodies 
cannot  bind  or  neutralize  VacCGtND  recombinant  virus. 
CD40L-deficient  and  normal  mice  were  infected  with 
VSV  and  8  d  later the VSV primed mice  as well as naive 
control animals were challenged intraperitoneally by infec- 
tion with VacCGIND- Vaccinia titers in the ovaries were de- 
termined 5  d  after challenge (Fig. 8).  As with the foot pad 
swelling results  (Fig. 7  B),  we  did not  observe  a  reduced 
CD4 + T  cell mediated antiviral erector function in CD40L- 
deficient as compared to CD40L-competent mice. 
Figure 8.  CD4 + T cell dependent 
protection  against challenge infec- 
tion  with  recombinant vaccinia vi- 
res.  CD40L-deficient  and  normal 
C57/BL6  mice  were  immunized 
with 2 ￿  106 PFU of VSV and 8 d 
later these primed mice as well as na- 
ive  control  mice  were  challenged 
i.p.  with  5  X  106  PFU VacCGIND. 
Vaccinia titers in ovaries were deter- 
mined 5 d after challenge infection. 
One of two experiment is shown. 
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Discussion 
Many  reports  have  focussed  on  the  key importance  of 
the  CD40-CD40L  interaction  for  the  generation  of hu- 
moral immune  responses  (1-6).  This  was  confirmed  here 
for  antiviral  IgG  immune  responses.  In  contrast  to  most 
previous reports, this study examined in addition the role 
of CD40-CD40L  interaction on Th cell activation, prolif- 
eration and erector functions. Surprisingly, neither Th cell 
induction nor Th cell erector functions other than cognate 
help  for  B  cells  were  compromised  by  the  lack  of the 
CD40- or the CD40L molecules. 
CD40  is expressed on  different APCs  such  as dendritic 
cells and B  cells and macrophages  (19-23).  In addition, it 
has  been  shown  that  CD40-CD40L  interaction  induces 
upregulation  of MHC  class II, B7  and  ICAM-1  on  den- 
dritic cell lines which potentiate the stimulatory capacity of 
the APC  (50).  The  CD40-CD40L  interaction-dependent 
upregulation of these and maybe other accessory molecules 
on the surface of the APC signals then back to the T  cell, a 
process which  may be  supported by interleukins in  addi- 
tion. Thus,  it could be expected that activation and prolif- 
eration  of specific Th  cells would be  impaired in  the  ab- 
sence of the CD40-CD40L  interaction as in fact has been 
recently reported  (51,  52).  However,  we report here that 
antigen-specific Th  cells are  induced  normally in  vivo in 
the absence of a functional CD40-CD40L  interaction after 
two  different virus infections; hence  the formation of this 
receptor-ligand pair is apparently not critical for the activa- 
tion of naive virus-specific Th cells. Since B  ceil activation 
and proliferation seems to depend critically upon the pres- 
ence  of cognate T-help  (5,  7,  53,  54),  absence of CD40- 
CD40L interaction will interfere with proliferation of spe- 
CD40-CD40 Ligand Interactions Are Not Critical for Anti-viral CD4 + T Cell Functions cific B  cells and therefore reduce class II associated antigen 
presentation by specific B cells. Because it has been reported 
that  antigen  presentation  by B  cells  is  important  for the 
normal induction  of T-helper cells  in several systems (38- 
44),  our results suggest that either B  cell proliferation and 
activation is impaired to a smaller degree than expected in 
the absence of CD40-CD40L interaction,  or, alternatively 
and more likely, that the presence of specific B  cells plays 
only a minor if any role for the induction of T-helper cells 
with the infectious virus-derived antigens studied here (55). 
This latter possibility is supported by the fact, that Th cells 
primed in the absence of B  cells proliferated normally and 
could mediate isotype switch after adoptive transfer (Fig.  3, 
C  and D).  These findings  are in contrast to recently pre- 
sented data (51,  52). Grewal et al.  (51) showed a significant 
impairment  of KLH- or  HEL-specific T  cell  priming in 
mice lacking CD40 ligand. This impairment was evidenced 
by strongly reduced recall proliferation responses and by a 
failure of adoptively transferred CD40L-deficient T  cells to 
expand  in  vivo  after  antigenic  challenge.  In  contrast  to 
these findings, van Essen et al. observed normal KLH-spe- 
cific Th cell induction in CD40-deficient mice, but described 
these  KLH-primed T  cells  as being qualitatively  different 
from T  cells  primed in  a  CD40-competent  environment; 
they were apparently not able to provide help to B  cells. 
These  differences  concerning  the  importance  of a  func- 
tional CD40-CD40L interaction for the induction and ef- 
fector functions ofT cells between the virus models used in 
this  study  and  the  soluble  KLH  antigen  system  used  by 
Grewal et al.  (51) and by van Essen et al.  (52) probably re- 
flect different critical in vivo mechanisms governing both 
the induction and effector functions ofT cells. There are at 
least two possible explanations that might account for these 
differences: (a) The efficient activation ofT cells after a vi- 
ral infection such as with LCMV might over-ride some of 
the more subtle requirements for responses to soluble pro- 
tein  antigens  such  as  KLH.  In  addition,  the  failure  of 
CD40-deficient mice to resolve a Leishmania infection (H. 
Kikutani,  personal  communication),  despite  exhibiting  a 
Leishmania-resistant genetic background,  could be due to 
the lack of CD40 signals  to macrophages or dendritic cells 
which then could lead to a deficit in IL-12 production and 
therefore to an impaired Thl  development. Additional ev- 
idence for a requirement of a functional CD40-CD40L in- 
teraction for IL-12 induction in vivo and hence the induc- 
tion  of a  Thl  response  has  recently  been  presented  by 
Stfiber et al.  (56).  Thus, T  helper cells may influence their 
responses via CD40L  indirectly by activating their APCs. 
In a viral infection the direct secretion of IFN and possibly 
other interleukins by T  cells  may render this pathway less 
critical.  (b) Alternatively, B  cells may be of key importance 
as APCs for T  cell induction in a soluble antigen system in 
contrast to virus model infections.  There still  exists an un- 
resolved  controversy on  the  issue  whether  B  cells  play a 
central role in  the  initiation  of T  cell immune responses. 
Even studies  using the  same experimental antigen  such as 
KLH as soluble antigen and B  cell-deficient mice revealed 
different  results:  Epstein  et  al.  (57)  reported  successful  T 
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cell priming in B  cell-deficient mice using KLH as antigen 
whereas Liu et al.  (44)  failed to obtain T  cell priming in B 
cell-deficient  mice  using  either KLH  or  OVA  as  soluble 
protein  antigens.  Constant  et  al.  (58)  demonstrated  that 
mice lacking B  cells  were impaired in their priming of T 
cells to protein but not to peptide antigens. This dominant 
role of B  cells  as APCs found in several experimental sys- 
tems  using  soluble  antigens  is  possibly  abrogated  if the 
CD40 signaling pathway is not functional. We deliberately 
chose an experimental system where T  cell induction is not 
dependent on B cells functioning as APCs and analyzed the 
role of CD40-CD40L interaction in T  cell priming and Th 
cell effector functions independently of the presence or ab- 
sence of B cells. 
The effector functions of Th cells are differentially influ- 
enced  by  CD40-CD40L  interaction.  Thymus-dependent 
Ig-isotype switched humoral immune responses are com= 
pletely  abrogated  in  CD40-  or  CD40L-deficient  mice 
whereas  thymus-independent  IgM-responses  to  VSV  are 
comparable to normal mice; the latter apparently do not re- 
quire a functional interaction between CD40 and its ligand. 
Although  T-helper  cells  do  not  induce  antibody  isotype 
switching in B  cells in the absence of CD40-CD40L inter- 
action,  CD4 +  T  cells  could  be  functionally  primed  in 
CD40-deficient mice since upon transfer they were able to 
provide help for CD40-competent B  cells to undergo iso- 
type  switch.  These  findings  are  in  contrast  to  the  recent 
data of van Essen et al.  (52)  showing that KLH-specific T 
cells primed in a CD40-deficient environment are not able 
to help CD40-competent B cells. Although the experimental 
setups  are not identical,  it can be concluded  that  Th cell 
priming by virus infection seems to be considerably more 
efficient in a CD40-deficient environment than is possible 
for soluble protein antigens. Not only were induction, pro- 
liferation and cytokine production of specific T-helper cells 
normal  in  the  absence  of CD40-CD40L  interaction  but 
also effector functions of T-helper cells other than mediat- 
ing Ig isotype switching were largely normal in the absence 
of CD40 or CD40L.  CD4 § T  cell mediated inflammatory 
reaction  upon  LCMV  infection  was  not  impaired  in 
CD40-  or  CD40L-deficient  mice.  In  addition,  Th  cell- 
dependent  antiviral  protection  was  not  impaired  by  the 
lack of CD40-CD40L  interaction:  activated VSV-specific 
Th cells in CD40L-deficient mice were able to inhibit the 
replication of VSV-G recombinant vaccinia virus by a cyto- 
kine mediated effector function; this protective Th cell func- 
tion has been shown to be mediated by release oflFNy and 
TNFot  by  activated  CD4 §  Th  cells  (37).  It  has  recently 
been suggested,  that CD40L may exert a direct protective 
effect against vaccinia virus  (59).  Our  data  show that  Th 
cells can efficiently protect against vaccinia virus replication 
also in the absence of CD40L, suggesting that this parame- 
ter is not limiting under the conditions tested in vivo. 
In  conclusion,  these  results  reveal  a  dichotomy in  the 
role  of the  CD40-CD40L  interaction  in  Th  cell  effector 
functions: the functional interaction is of critical importance 
in  T-B  cell  cooperation  for  the  induction  of  thymus- 
dependent humoral immune responses but the same inter- action is not limiting for Th cell mediated effector functions 
such  as  virus-induced  inflammatory  reactions  or  antiviral 
protection, which probably depend on interactions between 
Th cells with macrophages and/or dendritic cells.  Our data 
strongly  suggest  that  CD40-CD40L  interaction  divides 
anti-viral Th cell effector functions in two categories: one 
category consisting of cognate T  help mediating B cell acti- 
vation followed by Ig class  switching which is strictly de- 
pendent  on a functional  CD40-CD40L interaction;  and a 
second category, represented in this report by virus-induced, 
CD4 + T  cell-mediated inflammatory reaction as well as an- 
tiviral  protection  is  largely  independent  of a  functional 
CD40-CD40L interaction.  Similarly, activation and prolif- 
eration  of Th  cells,  albeit  not a  Th  cell effector function, 
may  be  placed  in  this  second  category.  Thus,  CD40- 
CD40L interaction is critically and probably unidirection- 
ally-needed  for  B  cell  activation  followed  by  Ig  class 
switch,  but in addition is possibly of importance for mac- 
rophage/dendritic  cell  activation  especially  in  the  case  of 
nonviral antigens. 
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